Addex Therapeutics (ADXN)
(Delayed Data from NSDQ)
$8.00 USD
-0.12 (-1.48%)
Updated Jul 24, 2024 09:58 AM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Addex Therapeutics Ltd. Sponsored ADR [ADXN]
Reports for Purchase
Showing records 1 - 18 ( 18 total )
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Optimized Entry and Exit Levels for ADXN 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
ADX71149 Data in 2Q24; Eurostars Grant Awarded; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Research Collaboration Extended; 2Q22 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Equity Financing Complete; Cash Runway Lengthened; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Dipraglurant Clinical Program Discontinuation; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Blepharospasm Trial Inconclusive; 1Q22 Financials; Lowering PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Dipraglurant Phase 2 Enrollment Completed; Pipeline Expands; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Blepharospasm Phase 2 Data Near-Term; 2021 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Multiple Clinical Catalysts; Runway Lengthened; Reducing PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Dipraglurant Phase 2 Trial Advancing; 2Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Indivior Research Collaboration Extension; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Seminal mGluR2 Publication Opens Intriguing Lines of Inquiry; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Dipraglurant Pivotal Phase 2b/3 Trial Begins Screening Patients; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
ADX71149 Phase 2 Epilepsy Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Dipraglurant Rescues Synaptic Plasticity in Dystonia Models; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Dipraglurant Pivotal Trial Initiation Imminent; 1Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
An Underrated Leader in Allosteric Modulation; Initiating at Buy and $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
|